Annexon Biosciences

2 followers


Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye.

Org chart

Douglas Love
President & Chief Executive Officer

Douglas Love

Collapse
Michael Overdorf
EVP & Chief Business Officer
Rick Artis
Chief Scientific Officer
Jennifer Lew
EVP & Chief Financial Officer
Ted Yednock
EVP & Chief Innovation Officer
Dean Richard Artis
EVP And Chief Scientific Officer
Jamie Dananberg
EVP & Chief Medical Officer
AJ Acker
Senior Vice President, Regulatory, Quality & Clinical Safety
Cecilia Oliyai
Senior Vice President CMC Operations
John Hanna
VP & Head of Clinical Safety
Peter Collins
Vp, Global Program Team Lead - Neurodegeneration Franchise
Henk-Andre Kroon
Svp, Head Of Translational Medicine
Kunal Kanani
Vice President Regulatory Affairs

Board & advisors

Jung E. Choi
Board Member, Compensation Committee Chair, Science & Technology Committee
Muneer Satter
Board Member
Will Waddill
Board Member
Jeff Goldberg
Scientific Advisor
Stephen Hauser
Scientific Advisor
David Holtzman
Scientific Advisor
Tom Maniatis
Scientific Advisor
Beth Stevens
Scientific Advisor
Hugh Willison
Scientific Advisor